Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind trial of anastrozole (Arimidex) to delay epiphyseal fusion and increase height potential in adolescent males with growth hormone deficiency
2012-001183-30Phase 2
- Sponsor
- Nemours Children's Health
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in growth hormone deficiency (GHD) and hypopituitarism comparing Arimidex + growth hormone with Placebo + growth hormone (2 arms). Primary endpoint: Change in predicted adult height at 24 months.
02
Drugs
anastrozole
03
Conditions
growth hormone deficiency (GHD)hypopituitarism
Beyond the preview
Go deeper on 2012-001183-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001183-30.